• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Congratulation Roger and Ken!

Quote

Anonymous

Guest
What and amazing display of competence, focus, and resolve...."Keytruda embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases," CEO Kenneth Frazier said in a statement.
 








































This approval was a win for Merck, but Roger and Ken had nothing to do with it.

Let's not overlook the fact that the pipeline is empty, the products are dropping like flies, the stock is nowhere near where it was even ten years ago and the management is moral void.

If you own this stock, sell it NOW.
 








Anonymous said:
This approval was a win for Merck, but Roger and Ken had nothing to do with it.

Let's not overlook the fact that the pipeline is empty, the products are dropping like flies, the stock is nowhere near where it was even ten years ago and the management is moral void.

If you own this stock, sell it NOW.
Click to expand...

On Friday morning Jim Cramer said this was good news for Merck regarding the approval however he still has serious concerns about Merck's management.
 




Bristol-Myers Squibb filed a lawsuit in US district court seeking unspecified damages from Merck & Co. for allegedly infringing a new immunotherapy patent, Bloomberg reported Friday. According to the litigation, filed in federal court for the District of Delaware, Bristol-Myers Squibb claims "Merck is threatening to exploit that invention" with a later-developed method of treatment, in violation of a patent issued on May 20.
 








Anonymous said:
On Friday morning Jim Cramer said this was good news for Merck regarding the approval however he still has serious concerns about Merck's management.
Click to expand...

Cramer should be concerned...While Rodger and Ken can pat themselves for the speed with which this breakthrough was approved, the fact of the matter is the know- it- all MRL leadership sat on this compound- which BTW was developed by Organon---- for nearly three years while they build power point slides and committees to review the power point slides. They gutted almost every program, in both Oncology and PC to fund this catch up. Brilliant.
 




Pat Roger and Ken on the back all you want for finally getting a drug approved. However, do not count you chickens before they have hatched. Revenues in proportion to the needs of the company is what matters and that success should not be considered a forgone conclusion at this point.
 




Anonymous said:
Cramer should be concerned...While Rodger and Ken can pat themselves for the speed with which this breakthrough was approved, the fact of the matter is the know- it- all MRL leadership sat on this compound- which BTW was developed by Organon---- for nearly three years while they build power point slides and committees to review the power point slides. They gutted almost every program, in both Oncology and PC to fund this catch up. Brilliant.
Click to expand...

Did not realize this drug came from The research of Organon. Ken & Rodger should just close the labs and open up a real estate office. Seems to be their new business model.
 












Top Bottom
Back
Quote